A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance

Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) is the standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). Third-generation EGFR-TKIs, represented by osimertinib, have been approved to overcome the EGFR T790M mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Fanjie, Zhou, Yi, Yu, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670331/
https://www.ncbi.nlm.nih.gov/pubmed/34520433
http://dx.doi.org/10.1097/CAD.0000000000001242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670331/
https://www.ncbi.nlm.nih.gov/pubmed/34520433
http://dx.doi.org/10.1097/CAD.0000000000001242

Ejemplares similares